Alkeran

(melphalan)

ApprovedSmall molecule

Melphalan is a chemotherapy drug used to treat certain blood cancers, including multiple myeloma (cancer of blood cells in the bone marrow) and some types of lymphoma. It works by damaging cancer cell DNA to stop them from growing.[2] Alkeran is currently approved and in use across 69 indications[4].[1]

Alkeran is one of 898 small molecule programs targeting Neuroblastoma. It is currently in Approved.

Indications

594

Total Trials

Active Trials

897

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

NeuroblastomaTerminated

Acute Myeloid LeukemiaNot yet recruiting

Myelodysplastic SyndromeSuspended

LeukemiaNot yet recruiting

LymphomaCompleted

Non-Malignant DisordersTerminated

Bone Marrow TransplantActive, not recruiting

TransplantationCompleted

Anaplastic Large Cell LymphomaActive, not recruiting

Acute LeukemiaActive, not recruiting

NeuroblastomaPhase 3

Terminated

Acute Myeloid LeukemiaPhase 3

Not yet recruiting

Myelodysplastic SyndromePhase 3

Suspended

LeukemiaPhase 2

Not yet recruiting

LymphomaPhase 3

Completed

Non-Malignant DisordersPhase 2

Terminated

Bone Marrow TransplantPhase 2

Active, not recruiting

TransplantationPhase 2

Completed

Anaplastic Large Cell LymphomaPreclinical

Active, not recruiting

Acute LeukemiaPreclinical

Active, not recruiting

Showing 10 of 69 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Alkeran

AApotex Inc.

Approved

57 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Cabenuva

GSK

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Hematopoietic Stem Cell Transplantation

NCT04018937

Phase 2Recruiting

Neuroblastoma

NCT02605421

Phase 1/2Active, not recruiting

Multiple Myeloma

NCT01054196

Phase 3Recruiting

Conditioning

NCT06829472

N/AActive, not recruiting

Hematopoietic Stem Cell Transplant

NCT01652092

Phase 2Active, not recruiting

Malignancy

NCT03674411

Clinical

Trials by Indication[1]

Multiple Myeloma47 trials

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00305812·51 enrolled

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028886·450 enrolled

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Completed·MMargarida Magalhaes-Silverman·Phase 2·NCT01849783·41 enrolled

Show 44 more trials

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00405756·459 enrolled

Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00008229

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00427765·168 enrolled

Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·NNorthwestern University·Phase 3·NCT00004165

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Completed·—·Phase 2·NCT00792142·45 enrolled

Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

Terminated·UUniversity of Virginia·Phase 2·NCT01617213·1 enrolled

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002556·312 enrolled

High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

Terminated·UUniversity of Southampton·Phase 2·NCT00637767·25 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00005792·131 enrolled

Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients

Terminated·FFondazione EMN Italy Onlus·Phase 2·NCT01116128·8 enrolled

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

Unknown status·—·Phase 3·NCT00747877·460 enrolled

Autologous Transplant for Multiple Myeloma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00177047·363 enrolled

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00028600·60 enrolled

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

Completed·WWen-Kai Weng·Phase 2·NCT00185614·63 enrolled

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Terminated·SSrinivas Devarakonda·Phase 2·NCT04205240·1 enrolled

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT01413178·205 enrolled

Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma

Unknown status·SShandong Lanjin Pharmaceuticals Co.,Ltd·N/A·NCT01572688·60 enrolled

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT04466475

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01998971·240 enrolled

FM 140 vs FM100 Study in Patients With Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00505895·52 enrolled

Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01045460·36 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00014508

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Active, not recruiting·WWeill Medical College of Cornell University·Phase 1/2·NCT01054196·52 enrolled

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002678·595 enrolled

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

Unknown status·EErasme University Hospital·Phase 2·NCT00526734·100 enrolled

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00054353·16 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Unknown status·—·Phase 2·NCT00004903

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Completed·PPETHEMA Foundation·Phase 2·NCT01237249·250 enrolled

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

Completed·MMayo Clinic·Phase 2·NCT00002630·50 enrolled

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00217438·130 enrolled

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Terminated·UUniversity of Colorado, Denver·Phase 1/2·NCT02353572·3 enrolled

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Withdrawn·OOncotherapeutics·Phase 2·NCT00085345

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00948922·124 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 1/2·NCT00046852

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Completed·SStanford University·Phase 2·NCT00349778·102 enrolled

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Withdrawn·—·Phase 1/2·NCT03100877

Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.

Completed·PPETHEMA Foundation·Phase 1/2·NCT00388635·60 enrolled

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Completed·OOncotherapeutics·Phase 1/2·NCT00743288·40 enrolled

Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma

Unknown status·MMedsearch·Phase 3·NCT00014339

Personalized Autologous Transplant for Multiple Myeloma

Recruiting·EEmory University·Phase 1·NCT04483206·90 enrolled

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Withdrawn·WWashington University School of Medicine·Phase 1·NCT02447055

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02331368·32 enrolled

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02504359·11 enrolled

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·—·Phase 2·NCT01605032·19 enrolled

Lymphoma19 trials

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00265889·42 enrolled

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Terminated·FFrench Innovative Leukemia Organisation·Phase 3·NCT00920153·442 enrolled

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00521014·14 enrolled

Show 16 more trials

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02130869·8 enrolled

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Suspended·—·Phase 2·NCT06692452·24 enrolled

Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)

Completed·SSoonchunhyang University Hospital·Phase 2·NCT03792815·51 enrolled

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003631·118 enrolled

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01625351·23 enrolled

Combination Chemotherapy in Treating Patients With Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002835·116 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Completed·—·N/A·NCT01702961·75 enrolled

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00907036·49 enrolled

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027937

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Withdrawn·FFred Hutchinson Cancer Center·N/A·NCT01769911

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

Unknown status·GGerman Hodgkin's Lymphoma Study Group·Phase 3·NCT00025636·220 enrolled

BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma

Completed·SSoonchunhyang University Hospital·Phase 2·NCT03794167·75 enrolled

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Completed·—·Phase 2·NCT00695409·122 enrolled

Auto Stem Cell Transplant for Lymphoma Patients

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03125642·150 enrolled

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00574496·25 enrolled

Neuroblastoma12 trials

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03786783·42 enrolled

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00567567·665 enrolled

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02605421·12 enrolled

Show 9 more trials

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Completed·CChildren's Oncology Group·Phase 1·NCT01175356·99 enrolled

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Completed·—·Phase 2·NCT00253435·50 enrolled

Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma

Completed·SSamsung Medical Center·Phase 2·NCT00793845·40 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT00017368·42 enrolled

Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Completed·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 2·NCT00017225

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·N/A·NCT00526318·360 enrolled

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00417053

High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01526603·13 enrolled

Hematologic Malignancies6 trials

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Completed·FFate Therapeutics·Phase 1·NCT00890500·12 enrolled

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01471067·33 enrolled

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Completed·SSally Arai·Phase 1·NCT00477035·22 enrolled

Show 3 more trials

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04264039·30 enrolled

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·RRoswell Park Cancer Institute·Phase 2·NCT01529827·94 enrolled

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT01745913·2 enrolled

Stem Cell Transplant5 trials

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00307086·30 enrolled

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Terminated·LLudwig Institute for Cancer Research·Phase 1·NCT02716805·6 enrolled

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT02483000·3 enrolled

Show 2 more trials

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

Completed·—·Phase 1·NCT00638898·25 enrolled

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Terminated·UUniversity of California, San Francisco·N/A·NCT00301860·8 enrolled

72 more indications

Amyloidosis5 trials

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00520767·35 enrolled

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00017680·25 enrolled

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Completed·—·Phase 2·NCT01083316·35 enrolled

Show 2 more trials

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Terminated· Takeda logo

Takeda·Phase 3·NCT01659658·177 enrolled

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01078454·11 enrolled

Melanoma4 trials

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

Completed·VVastra Gotaland Region·Phase 1·NCT04812470·8 enrolled

Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

Withdrawn·WWashington University School of Medicine·Phase 1/2·NCT01531244

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

Withdrawn·—·Phase 1·NCT00661336

Show 1 more trial

Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

Completed·—·Phase 1·NCT00565968·20 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation4 trials

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00523809·5 enrolled

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·UUniversity of California, Irvine·Phase 2·NCT06028828·60 enrolled

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00429026·40 enrolled

Show 1 more trial

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Terminated·MMontefiore Medical Center·Phase 1·NCT02653196·1 enrolled

Hematologic Cancer3 trials

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

Terminated·NNorthside Hospital, Inc.·Phase 2·NCT00827099·5 enrolled

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003661·3 enrolled

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer

Withdrawn·—·Phase 1·NCT00003435

Lymphoid Malignancies3 trials

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00472056·93 enrolled

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00968760·34 enrolled

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00439556·40 enrolled

Myelofibrosis3 trials

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03426969·3 enrolled

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

Withdrawn·—·Phase 1·NCT02528877

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Completed·—·Phase 1·NCT02917096·18 enrolled

Breast Cancer3 trials

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Completed·—·Phase 2·NCT00003042·41 enrolled

Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00429572·19 enrolled

High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00003392·61 enrolled

Hematopoietic Stem Cell Transplant3 trials

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01626092·3 enrolled

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01652092·57 enrolled

Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Completed·UUniversity of California, San Francisco··NCT03609827·25 enrolled

Allogeneic Stem Cell Transplantation3 trials

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

Terminated·UUniversity of Chicago·Phase 1·NCT00943293·1 enrolled

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01518153·16 enrolled

Allogeneic Stem Cell Transplantation for Children With CML

Completed·SSt. Anna Kinderkrebsforschung·Phase 2/3·NCT02707393·13 enrolled

Autologous Stem Cell Transplantation2 trials

Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation

Terminated·WWashington University School of Medicine·Phase 2·NCT01653418·10 enrolled

Autologous Stem Cell Transplantation for Crohn's Disease

Recruiting·PPaul Szabolcs·Phase 1/2·NCT00692939·20 enrolled

Retinoblastoma2 trials

Topotecan and Melphalan for Retinoblastoma

Recruiting·SSun Yat-sen University·Phase 3·NCT04799002·50 enrolled

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

Terminated·UUniversity of California, San Francisco·Phase 1·NCT02116959·6 enrolled

Stem Cell Transplantation2 trials

Allogeneic Blood Stem Cell Transplantation

Completed·MM.D. Anderson Cancer Center·N/A·NCT00423709·46 enrolled

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03615105·9 enrolled

Hematopoietic Stem Cell Transplantation2 trials

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00824135·34 enrolled

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

Active, not recruiting·EEmory University·Phase 2·NCT04018937·43 enrolled

Primary Systemic Amyloidosis2 trials

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Terminated·EEastern Cooperative Oncology Group·Phase 1·NCT00052884·8 enrolled

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Completed·MMayo Clinic·Phase 3·NCT00477971·89 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT02589145·8 enrolled

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Completed·LLymphoma Study Association·Phase 3·NCT00137995·481 enrolled

Acute Myeloid Leukemia2 trials

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Completed·IInstitut Paoli-Calmettes·Phase 1/2·NCT00840684·135 enrolled

Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 1·NCT00004056·35 enrolled

Germ Cell Tumor2 trials

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor

Unknown status·SSamsung Medical Center·Phase 2·NCT02784054·25 enrolled

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00002594·31 enrolled

Relapse2 trials

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Terminated·—·Phase 3·NCT02366663·3 enrolled

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

Completed·NNorthside Hospital, Inc.·Phase 2·NCT02771197·20 enrolled

Mantle Cell Lymphoma2 trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006747·4 enrolled

Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00720447·25 enrolled

Memory2 trials

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07052370·30 enrolled

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT02790515·170 enrolled

Donor2 trials

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Terminated·MMemorial Sloan Kettering Cancer Center·N/A·NCT01598025·3 enrolled

URMC Related Haplo-identical Donor BMT

Completed·UUniversity of Rochester·Phase 1·NCT02660281·74 enrolled

Chemotherapy2 trials

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00936936·64 enrolled

Intra-arterial Chemotherapy for Spinal Metastases

Completed·WWeill Medical College of Cornell University·Phase 1·NCT01637766·12 enrolled

Conditioning2 trials

Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT06829472·120 enrolled

Reduced Intensity Conditioning Transplant Using Haploidentical Donors

Completed·NNorthside Hospital, Inc.·Phase 2·NCT02581007·25 enrolled

Colorectal Cancer2 trials

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00089401·8 enrolled

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00019760

Children1 trial

A Pharmacokinetic Study of Melphalan in Children

Completed·—·Phase 1·NCT02390544·34 enrolled

Graft Versus Host Disease1 trial

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

Hepatocellular Carcinoma1 trial

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Terminated·DDelcath Systems Inc.·Phase 2·NCT02415036·17 enrolled

Malignant Disease1 trial

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038857·29 enrolled

Gemcitabine1 trial

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01237951·75 enrolled

Macroglobulinemia1 trial

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00003416·9 enrolled

Ovarian Cancer1 trial

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00583622·13 enrolled

Pneumonia1 trial

Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia

Unknown status·—·Phase 2·NCT04380376·60 enrolled

Hematopoietic Cell Transplantation1 trial

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Terminated·WWashington University School of Medicine·Phase 1·NCT02750254·5 enrolled

Sickle Cell Disease1 trial

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

Brain Cancer1 trial

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04521946

Unilateral Retinoblastoma1 trial

Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma

Completed·CChildren's Oncology Group·Phase 1·NCT02097134·14 enrolled

Unresectable Cancer1 trial

A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001587·30 enrolled

Acute Lymphoblastic Leukemia1 trial

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·UUniversity College, London··NCT01085617

Myeloma1 trial

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00002548·899 enrolled

Ewing sarcoma1 trial

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Withdrawn·—·N/A·NCT01795430

Myelodysplastic Syndrome1 trial

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

Active, not recruiting·—·Phase 2·NCT04339101·59 enrolled

Myeloid Neoplasm1 trial

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Completed·UUniversity of Washington·Phase 2·NCT02756572·30 enrolled

Prostate Cancer1 trial

A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

Terminated·BBarts & The London NHS Trust·Phase 2/3·NCT01907009·29 enrolled

Metastatic Cancer1 trial

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Recruiting·GGeneral Oncology, Inc.·Phase 1·NCT04150042·24 enrolled

Anemia1 trial

Stem Cell Transplantation for Sickle Cell Anemia

Completed·HHackensack Meridian Health·Phase 3·NCT01877837·30 enrolled

Hematopoietic Cell Transplant1 trial

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00410982·145 enrolled

Leukemia1 trial

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03856216·15 enrolled

Cutaneous T-cell lymphoma1 trial

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00506129·33 enrolled

Hematological Malignancies1 trial

Stem Cell Transplantation for Hematological Malignancies

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00176839·11 enrolled

Meningitis1 trial

Melphalan in Patients With Neoplastic Meningitis

Completed·—·Phase 1·NCT00002750·6 enrolled

Malignancies1 trial

Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)

Terminated·UUniversity College, London·Phase 2·NCT02310997·11 enrolled

Bone Marrow Transplantation1 trial

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Completed·MMedical College of Wisconsin·Phase 2·NCT02766465·138 enrolled

Langerhans Cell Histiocytosis1 trial

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00618540·1 enrolled

Patients With Solid Tumors1 trial

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00003926·13 enrolled

Genetic Disorder1 trial

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008307·52 enrolled

Recurrent or Refractory Solid Tumors1 trial

Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003899

Malignant Solid Tumors1 trial

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00436761·20 enrolled

Relapsed or Refractory1 trial

Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025103·75 enrolled

Myelodysplastic Syndromes1 trial

Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

Completed·—·Phase 1·NCT00641030·20 enrolled

Locally Advanced1 trial

Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00181025·33 enrolled

Solid Tumors1 trial

MT2004-30: Tomotherapy for Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00623077·23 enrolled

Pilot Study1 trial

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Completed·—·Phase 2·NCT00003336·6 enrolled

Transplantation1 trial

Pilot Study of Unrelated Cord Blood Transplantation

Terminated·KKing's College Hospital NHS Trust·Phase 2·NCT00916045·40 enrolled

Tic Disorder1 trial

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00176865·19 enrolled

Chronic Lymphocytic Leukemia1 trial

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003402·35 enrolled

Remission1 trial

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00869232·90 enrolled

HIV1 trial

Autologous Transplant in HIV Patients (BMT CTN 0803)

Completed·MMedical College of Wisconsin·Phase 2·NCT01141712·43 enrolled

Chronic Myelogenous Leukemia1 trial

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01904136·54 enrolled

Aplastic Anemia1 trial

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2/3·NCT00003816·361 enrolled

Malignancy1 trial

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03674411·22 enrolled

Stem Cell1 trial

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00651937·80 enrolled

Unspecified3 trials

Cellular Therapy With Cord Blood Cells

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00427557·31 enrolled

Twice-per-weekSelinexor, 2 Days Melphalan

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 3·NCT06613035·126 enrolled

N99-02: Melphalan and Buthionine Sulfoximine

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT00005835·31 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ALKERAN

NDA NDA014691

Nov 18, 1992

ALKERAN

NDA NDA020207

Mar 10, 2016

EVOMELA

NDA NDA207155

Aug 14, 2023

HEPZATO

NDA NDA201848

Aug 18, 2023

IVRA

NDA NDA217110

Sources

References

[1]
ClinicalTrials.gov — 594 trial records for melphalan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Alkeran drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — melphalan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for melphalan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217110). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Alkeran. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Apotex Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AApotex Inc.

Patent Landscape[6]

Patent Cliff

May 28, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11020363May 28, 2030

10864183May 28, 2030

10940128Jun 14, 2030

10369264Nov 7, 2032

10098997Nov 7, 2032

10 more patents

11633528Nov 7, 2032

11241522Nov 7, 2032

10569004Nov 7, 2032

11083831Dec 30, 2032

11833286Dec 30, 2032

10195334Jan 16, 2033

10040872Jan 30, 2034

9314561Feb 7, 2034

9707331Sep 17, 2034

10537520Jun 29, 2036